Phathom Pharmaceuticals (PHAT) Assets (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Assets of $327.1 million for Q2 2026, up 30.71% year-over-year from $250.2 million in Q2 2025, and up 7.2% quarter-over-quarter from $305.1 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Assets (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Assets for 9 consecutive years, with $327.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets rose 30.71% year-over-year to $327.1 million; the TTM figure through Jun 2026 stood at $327.1 million (up 30.71% YoY), while the FY2025 annual figure was $259.1 million, down 31.5% from the prior year.
- Assets advanced to $327.1 million in Q2 2026 per PHAT's latest filing, from $305.1 million in the prior quarter.
- Across five years, Assets topped out at $413.8 million in Q4 2023 and bottomed at $144.0 million in Q1 2023.
- Historically, Assets has averaged $272.6 million across 5 years, with a median of $262.1 million in 2023.
- Annual changes were most pronounced in 2022 — Assets tumbled 39.5% — and 2023, when it jumped 151.1%.
- Phathom Pharmaceuticals' Assets stood at $164.8 million in 2022, then surged by 151.1% to $413.8 million in 2023, then declined by 8.58% to $378.3 million in 2024, then sank by 31.5% to $259.1 million in 2025, then gained by 26.21% to $327.1 million in 2026.
- Business Quant data shows PHAT's Assets at $327.1 million in Q2 2026, $305.1 million in Q1 2026, and $259.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 327.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 327.08 Mn |
| Mar 31, 2026 | 305.12 Mn |
| Dec 31, 2025 | 259.15 Mn |
| Sep 30, 2025 | 240.29 Mn |
| Jun 30, 2025 | 250.22 Mn |
| Mar 31, 2025 | 294.21 Mn |
| Dec 31, 2024 | 378.32 Mn |
| Sep 30, 2024 | 387.04 Mn |
| Jun 30, 2024 | 319.38 Mn |
| Mar 31, 2024 | 356.50 Mn |
| Dec 31, 2023 | 413.84 Mn |
| Sep 30, 2023 | 236.99 Mn |
| Jun 30, 2023 | 265.04 Mn |
| Mar 31, 2023 | 144.01 Mn |
| Dec 31, 2022 | 164.81 Mn |
| Sep 30, 2022 | 201.93 Mn |
| Jun 30, 2022 | 213.50 Mn |
| Mar 31, 2022 | 149.05 Mn |
| Dec 31, 2021 | 189.43 Mn |
| Sep 30, 2021 | 228.38 Mn |